Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?
作者信息
Le Laura, van Dams Ritchell, Lee Percy
机构信息
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
出版信息
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S327-S330. doi: 10.21037/tlcr.2019.05.11.
Abstract
摘要
相似文献
1
Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?一线帕博利珠单抗是否适用于所有转移性非鳞状组织学类型的非小细胞肺癌患者？
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S327-S330. doi: 10.21037/tlcr.2019.05.11.
2
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.帕博利珠单抗对比标准治疗化疗用于 PD-L1 阳性（>50%）转移性鳞状和非鳞状非小细胞肺癌一线治疗的成本效果分析。在法国。
Lung Cancer. 2019 Jan;127:44-52. doi: 10.1016/j.lungcan.2018.11.008. Epub 2018 Nov 23.
3
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.免疫检查点抑制剂作为一线治疗方案，单独或联合化疗用于晚期非小细胞肺癌：一项系统评价和网络荟萃分析。
Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30.
4
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.帕博利珠单抗或安慰剂联合培美曲塞和铂类化疗用于未经治疗的转移性非鳞状非小细胞肺癌患者的疗效报告（KEYNOTE-189）：一项多中心、双盲、随机、安慰剂对照、III 期临床试验。
Lancet Oncol. 2020 Mar;21(3):387-397. doi: 10.1016/S1470-2045(19)30801-0. Epub 2020 Feb 6.
5
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.帕博利珠单抗联合化疗对比化疗联合帕博利珠单抗单药一线治疗美国鳞状非小细胞肺癌的成本效果分析。
Curr Med Res Opin. 2019 Jul;35(7):1241-1256. doi: 10.1080/03007995.2019.1571297. Epub 2019 Jan 29.
6
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.卡铂紫杉醇或nab-紫杉醇联合或不联合帕博利珠单抗治疗转移性鳞状非小细胞肺癌患者的健康相关生活质量。
J Clin Oncol. 2020 Jan 20;38(3):271-280. doi: 10.1200/JCO.19.01348. Epub 2019 Nov 21.
7
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.帕博利珠单抗联合化疗在美国非鳞状非小细胞肺癌一线治疗中的成本效益
J Med Econ. 2018 Dec;21(12):1191-1205. doi: 10.1080/13696998.2018.1521416. Epub 2018 Sep 21.
8
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.FDA 批准概要：帕博利珠单抗治疗转移性非小细胞肺癌：一线治疗及以上。
Oncologist. 2017 Nov;22(11):1392-1399. doi: 10.1634/theoncologist.2017-0078. Epub 2017 Aug 23.
9
Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.获批后一年接受纳武利尤单抗和帕博利珠单抗治疗的真实世界转移性非小细胞肺癌患者的特征。
Oncologist. 2018 Mar;23(3):328-336. doi: 10.1634/theoncologist.2017-0353. Epub 2018 Jan 9.
10
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.派姆单抗联合铂类化疗作为晚期非小细胞肺癌的一线治疗：KEYNOTE-021 研究的 1 期队列。
Lung Cancer. 2018 Nov;125:273-281. doi: 10.1016/j.lungcan.2018.08.019. Epub 2018 Aug 25.
引用本文的文献
1
Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study.帕博利珠单抗治疗晚期非小细胞肺癌的评估：一项回顾性、单中心、单臂研究。
J Thorac Dis. 2021 Jan;13(1):282-290. doi: 10.21037/jtd-20-3413.
2
Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors.第八版TNM分类的M描述符对接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者的预测和预后意义。
Transl Lung Cancer Res. 2020 Aug;9(4):1053-1066. doi: 10.21037/tlcr-19-396.
本文引用的文献
1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
2
Neoantigen-directed immune escape in lung cancer evolution.肺癌进化中的新抗原定向免疫逃逸。
Nature. 2019 Mar;567(7749):479-485. doi: 10.1038/s41586-019-1032-7. Epub 2019 Mar 20.
3
Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?铂类化疗在晚期非小细胞肺癌一线治疗中仍有作用吗？
J Clin Oncol. 2019 Mar 1;37(7):529-536. doi: 10.1200/JCO.18.01534. Epub 2019 Jan 24.
4
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
5
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
6
The effect of foxp3-overexpressing Treg cells on non-small cell lung cancer cells.Foxp3 过表达 Treg 细胞对非小细胞肺癌细胞的影响。
Mol Med Rep. 2018 Apr;17(4):5860-5868. doi: 10.3892/mmr.2018.8606. Epub 2018 Feb 13.
7
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.既往放疗与帕博利珠单抗治疗非小细胞肺癌的临床活性及毒性：KEYNOTE-001 1期试验的二次分析
Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.
8
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
9
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.用于癌症治疗的PD-L1（B7-H1）和PD-1通路阻断：作用机制、反应生物标志物及联合应用
Sci Transl Med. 2016 Mar 2;8(328):328rv4. doi: 10.1126/scitranslmed.aad7118.
10
Pembrolizumab for the treatment of non-small-cell lung cancer.帕博利珠单抗治疗非小细胞肺癌。
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
Zotero 插件